GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update

GT Biopharma, Inc. (NASDAQ:GTBP) was the recipient of a significant decrease in short interest during the month of February. As of February 27th, there was short interest totaling 2,089,377 shares, a decrease of 20.5% from the February 12th total of 2,629,402 shares. Currently, 20.3% of the company’s stock are short sold. Based on an average daily volume of 923,696 shares, the days-to-cover ratio is presently 2.3 days. Based on an average daily volume of 923,696 shares, the days-to-cover ratio is presently 2.3 days. Currently, 20.3% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of GT Biopharma in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, GT Biopharma has an average rating of “Sell”.

Hedge Funds Weigh In On GT Biopharma

An institutional investor recently raised its position in GT Biopharma stock. Bank of Montreal Can lifted its holdings in GT Biopharma, Inc. (NASDAQ:GTBP) by 531.6% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 92,530 shares of the company’s stock after buying an additional 77,879 shares during the period. Bank of Montreal Can owned approximately 2.83% of GT Biopharma worth $331,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.15% of the company’s stock.

GT Biopharma Price Performance

Shares of GTBP stock traded down $0.01 on Friday, hitting $0.41. The stock had a trading volume of 541,692 shares, compared to its average volume of 820,900. The business has a 50 day moving average of $0.57 and a 200 day moving average of $0.68. GT Biopharma has a 12-month low of $0.39 and a 12-month high of $3.85. The stock has a market cap of $4.41 million, a price-to-earnings ratio of -0.06 and a beta of 1.28.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).